FDA premarket approval records identify Foundation Medicine, Inc. as the applicant for two laboratory assays reviewed under product code PQP, described as a next generation sequencing oncology panel, somatic or germline variant detection system. The original approvals are P170019 for FoundationOne CDx, decided November 30, 2017, and P190032 for FoundationOne Liquid CDx, decided August 26, 2020. Both records list a Boston, Massachusetts street address for the applicant; that is a filing address, not a verified headquarters. The records do not identify a parent company, brand owner, customer base or commercial footprint. [1][2][3][4]

FoundationOne CDx and its documented scope

The P170019 approval describes FoundationOne CDx as a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations, and copy number alterations in 324 genes and select gene rearrangements, plus genomic signatures including microsatellite instability and tumor mutational burden, using DNA isolated from formalin-fixed paraffin embedded tumor tissue. The record states the test is intended as a companion diagnostic to identify patients, and its indication text names therapies including cetuximab, panitumumab and rucaparib alongside biomarkers such as KRAS and NRAS wild-type status and BRCA1/2 alterations. The original review carried an expedited review flag. [4]

A later supplement, P170019/S069, was approved September 16, 2026, after a March 20, 2026 receipt date. The approval statement describes an update to FoundationOne CDx labeling to include results of supplemental clinical data submitted in a Post-Approval Study Report. The supplement was filed on the normal 180-day track without user fee, with a labeling change reason tied to that report. [2]

FoundationOne Liquid CDx and its blood-based design

The P190032 approval describes FoundationOne Liquid CDx as a qualitative next generation sequencing based in vitro diagnostic test using targeted high throughput hybridization-based capture technology to detect and report substitutions, insertions and deletions in 311 genes, with rearrangements and copy number losses reported only in BRCA1 and BRCA2. The assay uses circulating cell-free DNA isolated from plasma derived from anti-coagulated peripheral whole blood. The record states the test is a single-site assay performed at Foundation Medicine, Inc. in Cambridge, Massachusetts, and that it is not labeled for use of any specific therapeutic product. [3]

The manufacturer's technical specifications describe the same assay as detecting and reporting genomic alterations in 311 genes, comprising substitutions, insertions and deletions in 311 genes, rearrangements in 8 genes and copy number alterations in 3 genes, using cfDNA from plasma collected in the company's cfDNA blood collection tubes. The technical information document lists intended use, contraindication, warnings and precautions, limitations and test principle among its contents, and includes companion diagnostic classification criteria for HRR gene alterations in prostate cancer. [5][6]

Recent process filing and published product description

P190032/S032 was received August 19, 2026, and decided September 18, 2026, under decision code OK30. The record identifies it as a 30-day notice for a process change involving manufacturer, sterilizer, packager or supplier, with an approval statement for a manufacturing process change. It is a supplement to the Liquid CDx approval, not a new device authorization. [1]

The manufacturer's product page describes FoundationOne Liquid CDx as a companion diagnostic test that analyzes guideline-recommended genes from a blood draw, calling it an FDA-approved blood-based test analyzing over 300 genes from a single sample, with next-generation sequencing methodology and peripheral whole blood as sample type. A footnote on that page states the test analyzes 324 genes using circulating cell-free DNA and is FDA-approved to report short variants in 311 genes, rearrangements in 8 genes and copy number alterations in 3 genes. These are company-published descriptions, not independent assessments. [7]

What the filing record shows and does not show

The linked collection contains four premarket approval records: three approvals and one 30-day notice. That count reflects the filings retrieved as of the snapshot date, not total company sales, total portfolio or safety performance. No recall records appear in the retrieved sample. The FDA database pages for P190032 and its S032 supplement provide the agency's standard PMA entry points, including links to approval-order documents, but the numbered sources do not establish clinical performance figures beyond the approval statements quoted here. [1][2][3][4][8][9][10]